Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
Document Type
Article
Publication Date
5-25-2020
Publication Title
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Clinical Institute
Cancer
Department
Earle A. Chiles Research Institute
Department
Oncology
Recommended Citation
Subbiah, Vivek; Hu, Mini I-Nan; Gainor, Justin F.; Mansfield, Aaron Scott; Alonso, Guzman; Taylor, Matthew H; Zhu, Viola Weijia; Lopez, Pilar Garrido; Amatu, Alessio; Doebele, Robert C.; Cassier, Philippe Alexandre; Keam, Bhumsuk; Schuler, Martin H.; Zhang, Hui; Clifford, Corinne; Palmer, Michael; Green, Jennifer; Turner, Christopher D.; and Curigliano, Giuseppe, "Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors." (2020). Articles, Abstracts, and Reports. 3761.
https://digitalcommons.providence.org/publications/3761
